ArticleArchives of endocrinology and metabolism2026
Evaluation of three inflammation-associated blood indices for predicting malignancy in thyroid nodules.
Article in Archives of endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Response to the letter to the editor: Evaluation of three inflammation-associated blood indices for predicting malignancy in thyroid nodules.Archives of endocrinology and metabolism · 2026Article
- Comment on: Evaluation of three inflammation-associated blood indices for predicting malignancy in thyroid nodules.Archives of endocrinology and metabolism · 2026Article
- Pan-immune inflammation value and system inflammation response index associated with prolonged hospital stay of thyroid nodule patients undergoing ultrasound-guided microwave ablation, both aged ≤55 years and > 55 years.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDifferentiated thyroid carcinoma (DTC) is the most common endocrine malignancy and usually has a favorable prognosis. However, both diagnostic and prognostic evaluations currently rely mainly on postoperative histopathological results. Systemic inflammation-based indices - such as the Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), and Pan-Immune Inflammation Value (PIV) - have recently emerged as potential biomarkers in various cancers. This study aimed to evaluate the diagnostic and prognostic utility of these indices in patients undergoing thyroid surgery. SUBJECTS AND
methodsThis retrospective study included 554 patients who underwent total thyroidectomy between 2014 and 2021. Tumors were categorized as benign or malignant according to final histopathology. SII, SIRI, and PIV were calculated from preoperative complete blood counts. Multivariate logistic regression was performed and included age, sex, thyroid-stimulating hormone (TSH) level, glycated hemoglobin (HbA1c) level, and diabetes status. Receiver operating characteristic (ROC) analysis was used to determine diagnostic performance.
resultsAmong 554 patients, 366 had benign and 188 had malignant tumors. Among the systemic inflammatory markers, only the SII differed significantly between groups (p = 0.002) and remained an independent predictor of malignancy in multivariate analysis (OR = 0.85 per 100-unit increase, p = 0.007). ROC analysis revealed an AUC of 0.597, with 65.8% sensitivity and 58.2% specificity. None of the indices demonstrated prognostic value in the subgroup analyses.
conclusionThe SII demonstrated independent but clinically limited diagnostic value in differentiating malignant from benign thyroid lesions. Although its accuracy was poor (AUC <0.6), the SII may serve as a low-cost adjunct within multivariable preoperative models, particularly in indeterminate cytology cases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.